Cellular Immunotherapy for Non-Small Cell Lung Cancer by Iovance Biotherapeutics for Non-Small Cell Lung Cancer: Likelihood of Approval

Cellular Immunotherapy for Non-Small Cell Lung Cancer is under clinical development by Iovance Biotherapeutics and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData, Phase II drugs for Non-Small Cell Lung Cancer have a 39% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Cellular Immunotherapy for Non-Small Cell Lung Cancer’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Cellular Immunotherapy for Non-Small Cell Lung Cancer overview

Cellular immunotherapy is under development for the treatment of non-small cell lung cancer. The therapeutic candidate is administered intravenously. It constitutes tumor infiltrating lymphocytes (TILs) isolated from the patient’s tumor further expanded and then infused back to the patient enabling patient robust immune response.

Iovance Biotherapeutics overview

Iovance Biotherapeutics (Iovance) is a biotechnology company that focuses on the development and commercialization of novel immunotherapy products for treating various cancers. It develops products based on its tumor-infiltrating lymphocyte (TIL) technology. The company’s lead product candidates include lifileucel is an autologous, ready-to-infuse cell therapy indicated for the treatment of melanoma and metastatic cervical cancer; and LN-145 for the treatment of head and neck cancer. The company also focuses on investigating TIL therapy for treatment of a range of cancer. The company operates a research facility in Tampa, Florida. Iovance is headquartered in San Carlos, California, the US.

For a complete picture of Cellular Immunotherapy for Non-Small Cell Lung Cancer’s drug-specific PTSR and LoA scores, buy the report here.